Tumor suppressor p53 is the most important target of HIPK2; thus, the inhibition of HIPK2 (e.g., by small interfering (si) RNA) impairs p53 function [33] and cancer cell response to anticancer therapies [34]. This evidence concerns the gene TP53 and cancer.